Five Prime Therapeutics, Inc. (FPRX): Price and Financial Metrics

Five Prime Therapeutics, Inc. (FPRX)

Today's Latest Price: $15.17 USD

0.58 (-3.68%)

Updated Jan 26 6:55pm

Add FPRX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

FPRX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for FPRX is 0.18 -- better than only 16.36% of US stocks.
  • With a price/sales ratio of 33.75, Five Prime Therapeutics Inc has a higher such ratio than 92.62% of stocks in our set.
  • The volatility of Five Prime Therapeutics Inc's share price is greater than that of 96.69% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to FPRX, based on their financial statements, market capitalization, and price volatility, are SURF, NVCN, XFOR, DCPH, and FOLD.
  • Visit FPRX's SEC page to see the company's official filings. To visit the company's web site, go to

FPRX Stock Price Chart Interactive Chart >

Price chart for FPRX

FPRX Price/Volume Stats

Current price $15.17 52-week high $24.70
Prev. close $15.75 52-week low $1.75
Day low $15.06 Volume 708,000
Day high $16.10 Avg. volume 1,152,031
50-day MA $17.67 Dividend yield N/A
200-day MA $8.12 Market Cap 577.04M

Five Prime Therapeutics, Inc. (FPRX) Company Bio

Five Prime Therapeutics discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. The company was founded in 2001 and is based in South San Francisco, California.

FPRX Latest News Stream

Event/Time News Detail
Loading, please wait...

FPRX Latest Social Stream

Loading social stream, please wait...

View Full FPRX Social Stream

Latest FPRX News From Around the Web

Below are the latest news stories about Five Prime Therapeutics Inc that investors may wish to consider to help them evaluate FPRX as an investment opportunity.

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers

Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemo

Yahoo | January 15, 2021

We're Hopeful That Five Prime Therapeutics (NASDAQ:FPRX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | December 21, 2020

Is FPRX A Good Stock To Buy Now?

Is Five Prime Therapeutics Inc (NASDAQ:FPRX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise […]

Yahoo | December 18, 2020

Why Five Prime Therapeutics Stock Gained 312% in November

Shares of the clinical-stage cancer specialist Five Prime Therapeutics (NASDAQ: FPRX) gained a stately 312% over the course of November, according to data from S&P Global Market Intelligence. The drugmaker's shares blasted higher last month in response to positive mid-stage trial data for its novel stomach cancer candidate known as bemarituzumab. Bemarituzumab, as a first-line treatment for fibroblast growth factor receptor 2b-positive (FGFR2b+) stomach cancer, is thought to be capable of generating combined U.S. and EU sales in the range of $700 million per year, according to Cowen analyst Boris Peaker.

Yahoo | December 8, 2020

These Were the 5 Best Cancer Stocks Of 2020

While potential new vaccines and treatments aimed at COVID-19 have been the big stars, companies focused on treating cancer have had a pretty good run as well. Here's why investors have been pushing their stock prices through the roof.

Yahoo | December 7, 2020

Read More 'FPRX' Stories Here

FPRX Price Returns

1-mo -20.99%
3-mo 210.22%
6-mo 157.12%
1-year 198.04%
3-year -31.45%
5-year -57.80%
YTD -10.82%
2020 270.59%
2019 -50.65%
2018 -57.57%
2017 -56.26%
2016 20.75%

Continue Researching FPRX

Here are a few links from around the web to help you further your research on Five Prime Therapeutics Inc's stock as an investment opportunity:

Five Prime Therapeutics Inc (FPRX) Stock Price | Nasdaq
Five Prime Therapeutics Inc (FPRX) Stock Quote, History and News - Yahoo Finance
Five Prime Therapeutics Inc (FPRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0123 seconds.